Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Sarcoma 2CNS 2Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Sarcoma, Myeloid 1Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1Blast Crisis 1

Interventions

fludarabine 63Cyclophosphamide 63venetoclax 57Azacitidine 52fludarabine phosphate 50Specimen Handling 44Whole-Body Irradiation 40ruxolitinib 37Mycophenolic Acid 37Tacrolimus 35Melphalan 32Busulfan 32Biopsy 32Cytarabine 31Stem Cell Transplantation 27Decitabine 27Granulocyte Colony-Stimulating Factor 21asciminib 19decitabine and cedazuridine drug combination 18Sirolimus 18Peripheral Blood Stem Cell Transplantation 18Injections 18Thiotepa 17Filgrastim 17nilotinib 15X-Rays 14Methotrexate 14Cyclosporine 14Imatinib Mesylate 13Magnetic Resonance Spectroscopy 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Razoxane × Myeloid × 1 year × Clear all
NCT03589729 2026-05-22

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
MyeloidOther hematologic neoplasmSarcoma

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡